Understanding biosynthesis in the cannabis sector

1 min read

On this episode of BofC Live, we connect with Dr. Mather Carscallen, the CEO and CTO of Algae-C – a plant biosynthesis company using algae to create plant-derived active pharmaceutical ingredients (APIs) – including cannabinoids. Carscallen describes the process of using algae for biosynthesis and the value it has to the cannabis sector – including cost, consistency and environmental impact.

BofC Live is the daily news and interview program of Business of Cannabis. Business of Cannabis highlights the companies, brands, people and trends driving the sector.

Learn more about Algae-C.


Listen to this episode of BofC Live, and all BofC Live episodes, as a podcast:


Previous Story

Does a political shake up benefit cannabis in Canada

Next Story

How to bring an NFL legend's blunt brand to market

0 $0.00